ChemoMetec stock
Price history
−10.26% over the period1 year: from kr 760.00 (November 20, 2025) to kr 682.00 (November 20, 2026), −10.26%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 20, 2026 | kr 682.00 |
| October 30, 2026 | kr 611.00 |
| September 30, 2026 | kr 523.00 |
| August 31, 2026 | kr 496.60 |
| July 31, 2026 | kr 432.60 |
| June 30, 2026 | kr 362.20 |
| May 29, 2026 | kr 375.00 |
| April 30, 2026 | kr 320.00 |
| March 31, 2026 | kr 300.80 |
| February 27, 2026 | kr 420.40 |
| January 30, 2026 | kr 609.50 |
| December 30, 2025 | kr 687.50 |
| November 28, 2025 | kr 782.50 |
| November 20, 2025 | kr 760.00 |
At a glance
The company
Develop and sell analytical equipment for cell counting and analysis used in cell therapy, pharmaceutical development, and quality control
Latest results
Quarter to September 30, 2026 · EPS kr 5.76 (estimate kr 3.92)
TickerLandia's take on ChemoMetec
- Priced as usual relative to earnings: P/E on the latest fiscal year 59 vs a median of 58 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 60 vs 29 (+107%) in a group of 10.
- Strong point: Profitability (95/100 in its group). Weak point: Earnings stability (39/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−13.45% from the 52-week high
Analysts · 3 analysts
Average targetkr 780.00+14.37% vs. price
Buy 3 · Hold 0 · Sell 0 · Strong buy
TickerLandia Fingerprint: ChemoMetec
Compared with similar companies: very high profitability, very high financial strength, and very high price.
Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Pricevery high92
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 59.9 84 Forward P/E 38.8 92 EV/EBITDA 43.4 92 Price/book 16.6 95 Price/sales 23.3 98 Profitabilityvery high95
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 49.1% 98 ROA 18.5% 95 Gross margin 95.1% 98 Net margin 39.5% 95 ROE 28.6% 89 Earnings stabilitylow39
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.8% 21 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 56 Growthaverage53
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +7.40% 50 Earnings growth (year over year) +51.30% 73 Average revenue growth (3 years) +4.77% 37 Financial strengthvery high93
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −1.07 85 Current ratio 4.09 89 Interest coverage 641.9 98 Debt/equitycounts in reverse: lower means more financial strength 0.01 98 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumstrong60
How the stock has moved compared with the market.
Metric Value Position in group 1-year return −10.26% 21 Distance from 200-day average +53.54% 100 Riskvery high92
How much the price swings.
Metric Value Position in group Maximum drawdown (12 months) 69.7% 99 Volatility (60 days) 42.4% 85
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 22, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
ChemoMetec is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2026), ChemoMetec's P/E today is 58.8, in line with the median of its last 10 fiscal years (58.5; between 31.2 and 166.1 from 2017 to 2026). ChemoMetec's P/E (trailing 12 months): 59.9, +107% against the median of a group of 10 similar companies (28.9).
Compared with 10 similar companies
| Metric | ChemoMetec | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 59.9 | High | |
| Forward P/E | 38.8 | High | |
| Operating margin | 49.1% | High | |
| ROE | 28.6% | High | |
| Debt/equity | 0.01 | Low |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: ChemoMetec. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
kr 262.04M
Latest quarter · Q2 2026
Net income
kr 107.86M
Latest quarter · Q2 2026
Quarterly net margin
41.2%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- kr 11.92B
- P/E
- 59.9
- EPS
- kr 11.60
- Volume
- 37.75K
- Daily trading
- €5.48M
How ChemoMetec is changing
All resultsRevenue grew 12.7% a year on average over the last 5 years
Operating margin fell from 51.9% to 49.1%
Profits turn into cash: free cash flow equal to 91% of net income
Returns
ChemoMetec returns with dividends
kr 1,000 invested in ChemoMetec 5 years ago, on November 22, 2021, would be worth kr 736 today with dividends reinvested: −26.36% in total, −5.94% per year. On price alone it would be kr 707 (−29.29%).
| Period | ChemoMetec | kr 1,000 becomes |
|---|---|---|
| 1 month | +18.40% | kr 1,184 |
| 6 months | +99.42% | kr 1,994 |
| Year to date | −0.80% | kr 992 |
| 1 year | −10.26% | kr 897 |
| 3 years | +90.37% | kr 1,904 |
| 5 years | −26.36% | kr 736 |
| 10 years | +1,865.42% | kr 19,654 |
From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment
The chart in detail
ChemoMetec: technical analysis
ChemoMetec shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 39.5% below its all-time closing high (kr 1,128.00, September 23, 2021).
- Trend
- No clear trend
- RSI (14 sessions)
- 59
- Between 30 and 70
- vs 200-session average
- +53.54%
Support and resistance
Price areas where ChemoMetec has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistancekr 736.25+7.95%4 touches, last on November 10, 2026
- Last pricekr 682.00
- Supportkr 601.75−11.77%2 touches, last on November 3, 2026
- Supportkr 534.25−21.66%2 touches, last on September 21, 2026
- Supportkr 464.80−31.85%2 touches, last on September 11, 2026
Volatility and risk
- Volatility (60 sessions, annualised)
- 42.4%
- Largest fall in the last year
- −69.74%
Close of November 20, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
ChemoMetec: seasonality
Average monthly price change over 20 years
Over the last 20 years, the strongest month for ChemoMetec has been January: +7.80% on average, positive in 11 years out of 20. The weakest has been March: −4.24% on average, positive in 6 years out of 20. November, the current month, has been positive in 9 years out of 19 (+4.08% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +7.80% | +4.18% | 11 of 20 |
| February | +3.10% | +1.92% | 12 of 20 |
| March | −4.24% | −2.77% | 6 of 20 |
| April | +1.77% | −0.31% | 9 of 20 |
| May | +4.09% | +5.52% | 13 of 20 |
| June | +0.91% | −3.33% | 9 of 20 |
| July | +7.68% | +2.70% | 13 of 20 |
| August | +2.85% | +2.81% | 12 of 20 |
| September | −2.78% | +1.26% | 11 of 20 |
| October | +5.95% | +0.67% | 10 of 20 |
| November | +4.08% | 0.00% | 9 of 19 |
| December | +1.15% | −3.45% | 6 of 19 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
ChemoMetec and its competitors
Analytical equipment for cell counting and analysis forms the core of the business of ChemoMetec, which sells its instruments in the United States, Canada, Europe and other international markets. Its NucleoCounter range, including the NC-3000 image cytometer, the NC-250 automated cell analyzer and the NC-203 cell counter for complex samples, serves customers working on advanced therapies, oncology and stem cell studies, and the development and production of medicines. The line also includes the SP-100 automated sperm cell counter for animal reproduction and the XcytoMatic 40 cell density and viability analyzer.
- Headquarters
- Allerød, Denmark
- Employees
- 174
- Founded
- 1997
- Chief executive
- Martin Behrens
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| ChemoMetecCHEMM | $1.75B | 49.1% | 59.9 | +99.42% |
| El.En.ELN | $1.44B | 14.7% | 20.7 | +10.78% |
| ElektaEKTA.B | $2.27B | 9.2% | — | +1.17% |
| Medacta GroupMOVE | $2.41B | 15.2% | 27.7 | −30.49% |
| GN Store NordGN | $2.46B | 10.9% | 90.2 | +22.10% |
| AmbuAMBU.B | $3.4B | 13.2% | 36.7 | +32.33% |
Same industry or related industries, similar size. Compare ChemoMetec with its competitors · Full profile
